A commercial rapid host-response test in COVID-19 severity stratification and triage
“SeptiCyte® RAPID can be processed using EDTA blood samples. The assay can distinguish COVID-19 cases with Severe or Critical presentation on CT from those with Mild or Moderate presentation.”
“SeptiCyte® RAPID proved superior to routinely used diagnostic tools for the differentiation of sepsis from infection negative systemic inflammation”
Use of SeptiCyte® RAPID Assay to Assess the Risk of ICU admission in COVID-19 Patients
“Diagnostic performance demonstrated that SeptiCyte® RAPID discriminated critical/severe COVID-19 cases from moderate/mild cases.”
“A study showing the performance of SeptiCyte RAPID in patients with malignancies and/or on anti-neoplastic or corticosteroid therapies”
“SeptiCyte® RAPID test is a rapid, repeatable, reproducible, near-patient, immune-response sepsis diagnostic, providing accurate results in ~ 1 hr to differentiate sepsis from SIRS”
In Silico Performance of a Rapid Sepsis Test in Patients with Candidemia
“SeptiCyte® RAPID differentiated patients with candidemia from those with INSI/SIRS, not infected and healthy subjects”
Clinical Performance of a Rapid Sepsis Test on a Near-Patient Molecular Testing Platform
“First demonstration of a validated, fully-integrated, rapid, repeatable, reproducible, near-patient, immune-response sepsis diagnostic”
“Preliminary diagnostic characteristics of SeptiCyte® RAPID test in differentiating sepsis from SIRS”
Accuracy of Septicyte® for Diagnosis of Sepsis Across a Broad Range of Patients
“The SeptiCyte® signature has broad diagnostic utility in heterogenous sepsis patient population”
“First quantification of uncertainty in sepsis diagnosis at admission, discharge and over the patient stay in a matched cohort”
“FDA-clearance study of the first gene signature assay for sepsis”
Sepsis Or SIRS? Actionable Results in About an Hour
“SeptiCyte® technology provides actionable results to aid early recognition and treatment of sepsis patients, independently of the presence of the causative pathogen”
Sensitive and Specific Diagnosis of Sepsis in Critically Ill Children Utilizing Host Gene Expression
“Pilot validation of the SeptiCyte® technology among critically ill children”